Y Intercept Hong Kong Ltd Buys Shares of 127,952 Climb Bio, Inc. $CLYM

Y Intercept Hong Kong Ltd bought a new position in shares of Climb Bio, Inc. (NASDAQ:CLYM) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 127,952 shares of the company’s stock, valued at approximately $159,000.

A number of other institutional investors and hedge funds also recently modified their holdings of CLYM. AQR Capital Management LLC acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $27,000. XTX Topco Ltd bought a new stake in Climb Bio in the first quarter valued at approximately $34,000. Nuveen LLC bought a new stake in Climb Bio in the first quarter valued at approximately $48,000. Bank of New York Mellon Corp acquired a new stake in Climb Bio in the first quarter worth $79,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Climb Bio during the first quarter worth $86,000. 69.76% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CLYM has been the subject of several research analyst reports. Baird R W raised shares of Climb Bio to a “strong-buy” rating in a report on Friday, August 15th. Robert W. Baird assumed coverage on Climb Bio in a report on Friday, August 15th. They set an “outperform” rating and a $9.00 target price on the stock. Wall Street Zen cut Climb Bio from a “hold” rating to a “strong sell” rating in a research note on Saturday. William Blair initiated coverage on Climb Bio in a report on Thursday, October 16th. They issued an “outperform” rating for the company. Finally, HC Wainwright assumed coverage on Climb Bio in a report on Monday, October 13th. They set a “buy” rating and a $9.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.20.

Climb Bio Trading Down 6.2%

Shares of NASDAQ CLYM opened at $1.83 on Monday. The company has a fifty day moving average price of $2.09 and a 200 day moving average price of $1.67. The firm has a market cap of $124.77 million, a PE ratio of -2.41 and a beta of -0.06. Climb Bio, Inc. has a 1-year low of $1.05 and a 1-year high of $4.34.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Equities research analysts forecast that Climb Bio, Inc. will post -1.57 EPS for the current year.

Climb Bio Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.